Dr. Kathryn Leake completed her Ph.D. from the University of North Texas Health Science Center in 2012 and a Postdoctoral Fellowship under Dr. Sheng-Xiang Lin of University Laval thereafter. She presently serves as Director of Oncology Solutions, a philanthropic organization that develops drugs for rare cancers. She has provisional patents on treatments for more than 8 malignancies, and several publications in reputed journals. Her research interests include estrogen studies associated with paracrine signaling in breast cancer, as well as virally-driven adenocarcinomas such as Inflammatory Breast Cancer and Triple Negative Breast Cancer. She has advised Immunologists on novel devices associated with diabetes and their immunological tolerance. Dr. Leake also specializes in Toxicology associated with drug resistance in multiple malignancies. Her treatment for chemo-drug resistance will benefit patients with the following malignancies: stomach cancer, bladder cancer, esophageal cancer, lung cancer, and kidney cancer. Several hematology patients should also benefit from the production of this novel drug target, and include Hodgkin’s Lymphoma, Multiple Myeloma and Acute Myelogenous Leukemia. Because developmental biology is associated with AML, she has also been invited to present her discoveries on overcoming failure to differentiate in Erythroleukemia, a rare type of myelogenous leukemia. International Presentation invitations include Keynote Speaker on Melanoma and Royal Academy Invitations in Drug Resistance. She presently serves as an Editorial Board member of both Insights in Blood Pressure and EC Pharmacology and Toxicology journals.
Philanthropic organization; Paracrine signaling in breast cancer; Virally-driven Adenocarcinomas; Toxicology; Drug resistance.